Paper32086972
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum.
Dubey D and 9 others. Ann Neurol, 2020. Cited by 173 papers, by iCite.
Cite this record
ConductScience Library. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Papers, record 32086972. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32086972
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics3
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Immunological | Major topic |
| Neurotoxicity Syndromes | Major topic |
| Humans |
Source PubMed
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 32368808 | Reply to "Value of Onconeural Antibodies in Checkpoint Inhibitor-Related Toxicities". | https://conductscience.org/library/papers/32368808 | PubMed |
| Comment in | 32386101 | Value of Onconeural Antibodies in Checkpoint Inhibitor-Related Toxicities. | https://conductscience.org/library/papers/32386101 | PubMed |
Cited by113
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 173 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42856915 | Efficacy and safety of immunotherapy in pediatric malignant brain tumors: a systematic review and exploratory meta-analysis. | Front Oncol | 2026 | https://conductscience.org/library/papers/42856915 | PubMed |
| 42853526 | Paraneoplastic Intracellular Neuropathies: A Narrative Review. | Neurol Ther | 2026 | https://conductscience.org/library/papers/42853526 | PubMed |
| 42841091 | Triple M Overlap Syndrome: A Rare Complication of Immune Checkpoint Inhibitors. | Cureus | 2026 | https://conductscience.org/library/papers/42841091 | PubMed |
| 42683203 | Immune-Related Encephalitis in a Patient With Pleural Mesothelioma: Case Report. | Respirol Case Rep | 2026 | https://conductscience.org/library/papers/42683203 | PubMed |
| 42488653 | Heterogeneity of immune checkpoint inhibitor-related inflammatory central nervous system adverse event reporting signals in primary and metastatic brain tumors: a pharmacovigilance study with single-cell and spatial transcriptomic contextualization. | Front Immunol | 2026 | https://conductscience.org/library/papers/42488653 | PubMed |
| 42488081 | Immune Checkpoint Inhibitor Associated Myopathy with Concurrent Myocardial Injury: A Retrospective Cohort Study. | Int J Gen Med | 2026 | https://conductscience.org/library/papers/42488081 | PubMed |
| 42342405 | Immune checkpoint inhibitor neurotoxicity: long-term outcomes with focus on 1-year neurological sequelae. | J Immunother Cancer | 2026 | https://conductscience.org/library/papers/42342405 | PubMed |
| 42227599 | Severe Immune-Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single-Center Study. | Eur J Neurol | 2026 | https://conductscience.org/library/papers/42227599 | PubMed |
| 42222387 | Case Report: Neurological immune-related adverse events with anti-PD-1 based immunotherapy in cervical cancer. | Front Oncol | 2026 | https://conductscience.org/library/papers/42222387 | PubMed |
| 42148066 | Severe neuromyelitis optica spectrum disorder induced by pucotenlimab: a case report and literature review. | Front Immunol | 2026 | https://conductscience.org/library/papers/42148066 | PubMed |
| 42029801 | Characterizing the effects of anti-PD1 immunotherapy on ataxia in a vestibular schwannoma mouse model. | J Neurooncol | 2026 | https://conductscience.org/library/papers/42029801 | PubMed |
| 41710645 | Successful Plasma Exchange and Steroid Maintenance Therapy for Severe Pembrolizumab-Induced Polyradiculoneuritis in Lung Cancer: A Case Report. | Case Rep Oncol | 2026 | https://conductscience.org/library/papers/41710645 | PubMed |
| 41488641 | Evaluation of warning strategies for paraneoplastic neurological syndromes associated with PD-1/PD-L1 inhibitors. | Front Immunol | 2025 | https://conductscience.org/library/papers/41488641 | PubMed |
| 41477245 | Encephalitis and Immune-Related Complications in a Patient Treated With Nivolumab: A Case Report. | Case Rep Med | 2025 | https://conductscience.org/library/papers/41477245 | PubMed |
| 41463186 | Specialist Neurology Involvement and Impact in Immune Checkpoint Inhibitor-Related Neurotoxicity: Experience in a Unified Healthcare System. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41463186 | PubMed |
| 41367883 | Fatal Steroid-Refractory Autoimmune Encephalitis Following Sequential Immune Checkpoint Inhibitor Therapy in Squamous Non-Small Cell Lung Cancer. | Onco Targets Ther | 2025 | https://conductscience.org/library/papers/41367883 | PubMed |
| 41350408 | Incidence and outcomes of neuromuscular immune-related adverse events in head and neck cancer patients treated with checkpoint inhibitors. | Sci Rep | 2025 | https://conductscience.org/library/papers/41350408 | PubMed |
| 41290313 | Neurological immune-related adverse events after ICI treatment: a protocol for an overview of systematic reviews. | BMJ Open | 2025 | https://conductscience.org/library/papers/41290313 | PubMed |
| 41052400 | Outcomes in Patients With Immune Checkpoint Inhibitor-Related Myopathy and Prolonged Follow-Up. | Neurol Neuroimmunol Neuroinflamm | 2025 | https://conductscience.org/library/papers/41052400 | PubMed |
| 40987493 | HLA-A*01:01-B*08:01-C*07:01 is linked to early-onset immune checkpoint inhibitor-induced myositis and myocarditis. | J Immunother Cancer | 2025 | https://conductscience.org/library/papers/40987493 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32086972
GET https://conductscience.org/api/papers/v1/32086972/cited_by?page=2